Goekbuget, Nicola and Basara, Nadezda and Baurmann, Herrad and Beck, Joachim and Brueggemann, Monika and Diedrich, Helmut and Gueldenzoph, Bjoern and Hartung, Gernot and Horst, Heinz-August and Huettmann, Andreas and Kobbe, Guido and Naumann, Ralph and Ratei, Richard and Reichle, Albrecht and Serve, Hubert and Stelljes, Matthias and Viardot, Andreas and Wattad, Mohammed and Hoelzer, Dieter (2011) High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. BLOOD, 118 (13). pp. 3504-3511. ISSN 0006-4971,
Full text not available from this repository. (Request a copy)Abstract
Nelarabine, a purine analog with T-cell specific action, has been approved for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (ALL/LBL). This is a report of a single-arm phase 2 study conducted in adults (18-81 years of age) with relapsed/refractory T-ALL/LBL. After 1 or 2 cycles, 45 of 126 evaluable patients (36%) achieved complete remission (CR), 12 partial remission (10%), and 66 (52%) were refractory. One treatment-related death was observed, and 2 patients were withdrawn before evaluation. A total of 80% of the CR patients were transferred to stem cell transplantation (SCT). Overall survival was 24% at 1 year (11% at 6 years). After subsequent SCT in CR, survival was 31% and relapse-free survival 37% at 3 years. Transplantation-related mortality was 11%. Neurologic toxicities of grade I-IV/grade III-IV were observed in 13%/4% of the cycles and 16%/7% of the patients. This largest study so far with nelarabine in adults showed impressive single-drug activity in relapsed T-ALL/T-LBL. The drug was well tolerated, even in heavily pretreated patients. A high proportion of CR patients were transferred to SCT with low mortality but a high relapse rate. Exploration of nelarabine in earlier stages of relapse (eg, increasing minimal residual disease), in front-line therapy, and in combination is warranted. (Blood. 2011;118(13):3504-3511)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | REFRACTORY HEMATOLOGIC MALIGNANCIES; MINIMAL RESIDUAL DISEASE; LEUKEMIA; ADULTS; LYMPHOMA; CHILDREN; PHARMACOKINETICS; 506U78; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 May 2020 11:36 |
| Last Modified: | 29 May 2020 11:36 |
| URI: | https://pred.uni-regensburg.de/id/eprint/20157 |
Actions (login required)
 |
View Item |
